title: Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: A
authors.initials: A
authors.lastname: Hanif
authors.affiliation: Department of Hematology and Oncology, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.
authors.forename: P N
authors.initials: PN
authors.lastname: Hari
authors.affiliation: Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: E
authors.initials: E
authors.lastname: Atallah
authors.affiliation: Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: K-S B
authors.initials: KS
authors.lastname: Carlson
authors.affiliation: Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Pasquini
authors.affiliation: Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: L C
authors.initials: LC
authors.lastname: Michaelis
mesh_terms: D064591:Allografts; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000401:mortality* / Q000628:therapy*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib